The FDA, CDC, and several gastroenterology societies have partnered to review ways to reduce duodenoscope-associated transmission of carbapenem-resistant Enterobacteriaceae.
Researchers conducted the first prospective study analyzing the efficacy offecal microbiota transplantation for patients with inflammatory bowel disease and C difficile infection.
In post-hoc analyses, researchers analyzed alcohol use data and whole-blood samples from 359 participants in the New Orleans Alcohol Use in HIV study to explore the association between intestinal leak, dysbiosis, and T cells.
This study assessed the contribution of the proximal small intestinal microbiota to stunting in an undernourished pediatric population who did not respond to nutritional intervention.
As the role of the gut microbiome in nonalcoholic fatty liver disease is explored, research has turned to fecal microbiota transplantation as a potential treatment option.
The gut microbiome has become one of the most researched topics in gastroenterology. However, it is not yet understood how changes to the gut microbiome affect certain malignancies, particularly colorectal cancer (CRC). Despite improvements in detection and prevention by colonoscopy and other forms of testing, CRC still has a significant effect on patient morbidity and…
Probiotics should only be recommended for specific patient populations since there is not enough evidence to support their use in the majority of digestive conditions, according to new clinical guidelines released by the American Gastroenterological Association (AGA) and recently published in Gastroenterology.
Depression alters the structure of the gut microbiome in patients with autoimmune hepatitis and could contribute to the progression of liver cirrhosis.
Depression alters the structure of the gut microbiome in patients with autoimmune hepatitis and could contribute to the progression of liver cirrhosis.
Fecal microbiota transplant (FMT) appears safe in decolonizing multi-drug resistant organisms (MDRO) from intestinal reservoirs in affected patients, even those who are highly immunosuppressed.
A novel rifabutin-based triple therapy (RHB-105) is effective for eradication of Helicobacter pylori, with eradication rates unaffected by resistance to clarithromycin or metronidazole.
